Drug Developer Roivant Hits $7.3B Valuation In SPAC Merger
Roivant Sciences will go public at a roughly $7.3 billion valuation by merging with a special purpose acquisition company backed by health care-focused investment shop Patient Square Capital, the companies said...To view the full article, register now.
Already a subscriber? Click here to view full article